Influences of cholecystokinin octapeptide on phosphoinositide turnover in neonatal-rat brain cells
- PMID: 1323276
- PMCID: PMC1132873
- DOI: 10.1042/bj2850847
Influences of cholecystokinin octapeptide on phosphoinositide turnover in neonatal-rat brain cells
Abstract
Cholecystokinin octapeptide (CCK-8) has been shown to be coupled to phosphoinositide turnover in pancreatic acini as well as in a kind of neuroblastoma cell and a human embryonic cell line. Little is known, however, about its link with phosphatidylinositol breakdown in the brain. The brains (minus cerebella) from 1-2-day-old neonatal rats were enzymically dissociated into single cells. The intact cells were prelabelled by incubation with myo-[3H]inositol for 3 h, and were then stimulated with agonists in the presence of 10 mM-LiCl. Carbachol at 1 mM induced an increase in InsP3 labelling in brain cells (peak at 30 min, and then a gradual decrease), and a static accumulation of InsP with time, whereas the labelling of InsP2 remained essentially unchanged. A very similar time-response curve was obtained for 10 nM-CCK-8 in stimulating phosphoinositide turnover. The dose-response curve for incubated brain cells revealed that the formation of InsP3 increased when the concentration of CCK-8 was increased from 0.1 to 10 nM. A further increase in CCK-8 concentration to 100-1000 nM resulted in a gradual decrease in InsP3 formation. InsP and InsP2 levels stayed relatively stable. The production of InsP3 stimulated by 10 nM-CCK-8 was dose-dependently suppressed by the CCK-A antagonist Devazepide in the concentration range 1-10 nM; the effect declined when the concentration was further increased to 100-1000 nM. In contrast, the CCK-B antagonist L365,260 showed a sustained suppression of InsP3 production at concentrations above 0.1 nM, i.e. in the range 1-1000 nM. The results provide evidence that CCK-8 stimulates the turnover of phosphoinositide and increases InsP3 labelling in dissociated neonatal-rat brain cells, in which both CCK-A and CCK-B receptors seem to be involved.
Similar articles
-
Characterization of a gastrin-type receptor on rabbit gastric parietal cells using L365,260 and L364,718.Am J Physiol. 1991 Feb;260(2 Pt 1):G182-8. doi: 10.1152/ajpgi.1991.260.2.G182. Am J Physiol. 1991. PMID: 1996638
-
CCKA receptor antagonism inhibits mechanisms underlying CCK-8-stimulated insulin release in isolated rat islets.Eur J Pharmacol. 1991 Sep 17;202(2):253-7. doi: 10.1016/0014-2999(91)90301-6. Eur J Pharmacol. 1991. PMID: 1666367
-
Characterisation of the effects of SR146131, a novel non-peptide CCK(1) receptor agonist, on IMR-32 human neuroblastoma cells.Eur J Pharmacol. 2000 Jun 2;397(2-3):303-10. doi: 10.1016/s0014-2999(00)00274-0. Eur J Pharmacol. 2000. PMID: 10844128
-
Functional role of brain CCK receptors.Neuropeptides. 1991 Jul;19 Suppl:45-56. doi: 10.1016/0143-4179(91)90082-t. Neuropeptides. 1991. PMID: 1881532 Review. No abstract available.
-
Some aspects on the anatomy and function of central cholecystokinin systems.Pharmacol Toxicol. 2002 Dec;91(6):382-6. doi: 10.1034/j.1600-0773.2002.910617.x. Pharmacol Toxicol. 2002. PMID: 12688383 Review.
Cited by
-
Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.CNS Drugs. 1997 Aug;8(2):134-52. doi: 10.2165/00023210-199708020-00005. CNS Drugs. 1997. PMID: 23338219
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources